Allogene Therapeutics Management
Management criteria checks 3/4
We currently do not have sufficient information about the CEO.
Key information
Zach Roberts
Chief executive officer
US$2.3m
Total compensation
| CEO salary percentage | 22.80% |
| CEO tenure | no data |
| CEO ownership | 0.06% |
| Management average tenure | 2.8yrs |
| Board average tenure | 8.3yrs |
Recent management updates
Recent updates
Seeking Alpha • Jul 04
Allogene Therapeutics: A High-Upside Bet On The Next Wave Of CAR-T Innovation
Summary Allogene Therapeutics offers upside potential driven by the pivotal ALPHA3 trial for Cema-cel in first-line large B-cell lymphoma, with a key readout in mid-2027. ALLO-329’s early clinical signals in autoimmune disease, leveraging proprietary Dagger technology, set up a differentiated, scalable CAR-T platform with high-value optionality. ALLO demonstrates improving financial discipline, reducing quarterly net loss to $42.6M and extending cash runway into early 2029 following a $200.4M public offering. Valuation reflects the discounted probability of clinical success, with catalysts including a 4Q26 ALLO-329 update and mid-2027 ALPHA3 EFS readout potentially driving re-rating. Read the full article on Seeking Alpha
Narrative Update • Jun 26
ALLO: ALPHA3 Trial Progress Will Drive Future Reassessment Of Risk And Reward
Analysts have adjusted their average price target for Allogene Therapeutics upward by about $1, citing updated models that reflect slightly higher estimated fair value, modestly different discount rate assumptions, and revised expectations for revenue growth, profit margins, and future P/E levels. Analyst Commentary Recent Street research around Allogene Therapeutics shows a mix of optimism and caution, with several firms adjusting ratings and price targets in response to new trial data, refreshed models, and evolving assumptions around revenue, margins, and future P/E levels.Analysis Article • Apr 10
Will Allogene Therapeutics (NASDAQ:ALLO) Spend Its Cash Wisely?
We can readily understand why investors are attracted to unprofitable companies. By way of example, Allogene...
New Narrative • Apr 02
MRD Guided Cell Therapy And Autoimmune Focus Will Transform Long Term Opportunity
Catalysts About Allogene Therapeutics Allogene Therapeutics develops off the shelf allogeneic CAR T cell therapies for cancer and autoimmune diseases. What are the underlying business or industry changes driving this perspective?New Narrative • Mar 19
Off The Shelf CAR T Therapies Will Reshape Lymphoma And Autoimmune Treatment Trajectories
Catalysts About Allogene Therapeutics Allogene Therapeutics develops off the shelf allogeneic CAR T cell therapies for cancer and autoimmune diseases. What are the underlying business or industry changes driving this perspective?
New Narrative • Mar 05
Allogeneic CAR T Expectations Will Likely Disappoint As Trial And Cash Runway Risks Mount
Catalysts About Allogene Therapeutics Allogene Therapeutics is a biotechnology company focused on developing off the shelf allogeneic CAR T cell therapies for cancer and autoimmune diseases. What are the underlying business or industry changes driving this perspective?Analysis Article • Jun 12
Shareholders May Find It Hard To Justify Increasing Allogene Therapeutics, Inc.'s (NASDAQ:ALLO) CEO Compensation For Now
Key Insights Allogene Therapeutics to hold its Annual General Meeting on 18th of June Salary of US$724.0k is part of...Analysis Article • Apr 02
Here's Why We're Watching Allogene Therapeutics' (NASDAQ:ALLO) Cash Burn Situation
Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...Seeking Alpha • Feb 25
Allogene Therapeutics: Disrupting CAR-T With A Scalable Model
Summary Allogene Therapeutics appears undervalued despite market skepticism, with a robust cash runway and potential breakthroughs in allogeneic CAR-T therapies. The company's lead asset, cema-cel, aims to shift CAR-T therapy to early intervention, potentially expanding its market and redefining treatment standards. ALLO-329 targets autoimmune diseases, positioning Allogene in a new market with significant unmet needs and less competition compared to oncology. Key risks include the efficacy and durability of allogeneic CAR-T therapies and manufacturing consistency, but early data and strategic positioning offer compelling upside potential. Read the full article on Seeking AlphaSeeking Alpha • Dec 10
Allogene Therapeutics: Showing Promise Despite Some Shaky Safety
Summary Allogene is among the pioneers in non-self engineered cell therapy. They have demonstrated encouraging early results in lymphoma, moving aggressively into a pivotal trial in the first-line setting. Their pivotal phase 2 trial ALPHA3 has the potential to change how large B-cell lymphoma is managed, but we won't have these results until 2026. Other projects, like their CD70-directed therapy, look promising but have concerning safety signals, and they're also a long way from approval. Read the full article on Seeking AlphaAnalysis Article • Nov 22
Is Allogene Therapeutics (NASDAQ:ALLO) In A Good Position To Invest In Growth?
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...Seeking Alpha • Aug 27
Allogene Therapeutics: Cema-Cel Promising Among Innovative CAR T-Cell Therapies
Summary Allogene Therapeutics is a clinical-stage biotech developing allogeneic CAR T therapies for cancer and autoimmune diseases, with a focus on Cema-cel for LBCL. ALLO's advanced gene-editing platforms, like TALEN and CRISPR/Cas9, engineer donor-derived T cells to overcome autologous therapy limitations, enhancing treatment safety and effectiveness. Cema-cel, the company’s flagship therapy, is in a pivotal Phase 2 trial (ALPHA3) for large B-cell lymphoma, with potential regulatory submission by 2027. Despite a promising pipeline, ALLO faces cash runway concerns, making it a suitable DCA “buy” for investors aware of clinical trial risks. ALLO's valuation is attractive, with a low P/B multiple and sufficient liquidity to fund operations until the ALPHA3 trial's primary data readout in 2026. Read the full article on Seeking AlphaSeeking Alpha • Jun 12
Allogene: Two End Of 2024 Data Readouts With Improved Allogeneic CAR-T Products
Summary Allogene Therapeutics, Inc. initiation of phase 2 ALPHA3 study, using cema-cel for the treatment of patients with 1st-line large B-cell lymphoma, expected in mid-2024 with two data analysis in 2026. Results from phase 2 ALPHA2 trial, using cema-cel for the treatment of patients with relapsed/refractory chronic lymphocytic leukemia, expected by end of 2024. Results from phase 1 TRAVERSE trial, using ALLO-316 for the treatment of CD70 positive clear cell renal cell carcinoma patients, expected by the end of 2024. Company gained rights from Servier to expand use of cema-cel for r/r CLL and 1st-line LBCL in European and U.K. territories; New potential to tap into >$9.5 billion market opportunity if approval is achieved for these indications. Read the full article on Seeking AlphaAnalysis Article • May 30
We Discuss Why Allogene Therapeutics, Inc.'s (NASDAQ:ALLO) CEO Compensation May Be Closely Reviewed
Key Insights Allogene Therapeutics to hold its Annual General Meeting on 5th of June Total pay for CEO David Chang...Seeking Alpha • Apr 01
Allogene Therapeutics: 2024 Platform Vision Sings Mid-Term Upside
Summary Allogene Therapeutics has announced changes to its pipeline that extend its financial runway into 2026. The new ALPHA3 clinical trial for Allogene's Cema-Cel cancer treatment is set to begin in mid-2024, and if successful, investors could see significant returns on their investment. The company's Q42023 report evidenced its financial distress. However, the 2024 platform vision, in my opinion, will have a positive impact on its profitability in the midterm. Given the lack of short-term revenue catalysts, with clinical trials expected to yield results by the end of 2024, investors will be required to be patient, while experiencing high volatility and potential share dilutions this year. Read the full article on Seeking AlphaAnalysis Article • Mar 01
We Think Allogene Therapeutics (NASDAQ:ALLO) Needs To Drive Business Growth Carefully
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Mar 31 2026 | n/a | n/a | -US$174m |
| Dec 31 2025 | US$2m | US$530k | -US$191m |
| Sep 30 2025 | n/a | n/a | -US$212m |
| Jun 30 2025 | n/a | n/a | -US$237m |
| Mar 31 2025 | n/a | n/a | -US$252m |
| Dec 31 2024 | US$2m | US$530k | -US$258m |
| Sep 30 2024 | n/a | n/a | -US$283m |
| Jun 30 2024 | n/a | n/a | -US$279m |
| Mar 31 2024 | n/a | n/a | -US$292m |
| Dec 31 2023 | US$8m | US$523k | -US$327m |
Compensation vs Market: Zach's total compensation ($USD2.33M) is below average for companies of similar size in the US market ($USD3.54M).
Compensation vs Earnings: Zach's compensation has increased whilst the company is unprofitable.
CEO
Zach Roberts (48 yo)
no data
Tenure
US$2,325,114
Compensation
Dr. Zachary J. Roberts, also known as Zach, M. D., Ph. D., serves as President, CEO & Director at Allogene Therapeutics, Inc. since July 1, 2026. Dr. Roberts served as Chief Medical Officer at Allogene The...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Co-Founder & Executive Chairman | 8.7yrs | US$4.08m | 1.76% $ 12.6m | |
| President | no data | US$2.33m | 0.056% $ 401.5k | |
| Co-Founder & Director | no data | US$170.07k | 0.12% $ 828.8k | |
| Co-Founder & Director | no data | US$6.14m | 1.72% $ 12.4m | |
| Executive VP & CFO | 2.8yrs | US$2.28m | 0.16% $ 1.1m | |
| Senior VP & Chief Technical Officer | 1.3yrs | no data | 0.057% $ 406.3k | |
| Senior VP | 2.9yrs | no data | 0.16% $ 1.2m | |
| Chief People Officer | 4.2yrs | no data | no data | |
| Executive VP | 3.5yrs | no data | no data | |
| SVP & Corporate Controller | 2.1yrs | no data | 0.036% $ 259.0k |
2.8yrs
Average Tenure
60yo
Average Age
Experienced Management: ALLO's management team is considered experienced (2.8 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Co-Founder & Executive Chairman | 8.7yrs | US$4.08m | 1.76% $ 12.6m | |
| President | no data | US$2.33m | 0.056% $ 401.5k | |
| Co-Founder & Director | 8.7yrs | US$170.07k | 0.12% $ 828.8k | |
| Co-Founder & Director | 8.1yrs | US$6.14m | 1.72% $ 12.4m | |
| Lead Independent Director | 8.3yrs | US$274.88k | 0.089% $ 639.6k | |
| Independent Director | 8.3yrs | US$193.07k | 0.085% $ 609.1k | |
| Member of Scientific Advisory Board | 7.2yrs | no data | no data | |
| Independent Director | 7.8yrs | US$193.07k | 0.031% $ 223.5k | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Chairman of Scientific Advisory Board | no data | no data | no data | |
| Independent Director | 8.3yrs | no data | no data |
8.3yrs
Average Tenure
67yo
Average Age
Experienced Board: ALLO's board of directors are considered experienced (8.3 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/07/06 15:50 |
| End of Day Share Price | 2026/07/02 00:00 |
| Earnings | 2026/03/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Allogene Therapeutics, Inc. is covered by 31 analysts. 10 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Jack Allen | Baird |
| Shanshan Xu | Berenberg |
| William Pickering | Bernstein |